Agios Pharmaceuticals Inc
Company Profile
Business description
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Contact
88 Sidney Street
CambridgeMA02139
USAT: +1 617 649-8600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
488
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,524.60 | 4.40 | 0.05% |
| CAC 40 | 7,836.79 | 37.04 | -0.47% |
| DAX 40 | 23,527.01 | 111.55 | -0.47% |
| Dow JONES (US) | 42,051.06 | 89.37 | -0.21% |
| FTSE 100 | 8,585.01 | 17.91 | -0.21% |
| HKSE | 23,565.70 | 74.95 | -0.32% |
| NASDAQ | 19,146.81 | 136.72 | 0.72% |
| Nikkei 225 | 37,705.74 | 422.39 | -1.11% |
| NZX 50 Index | 12,825.62 | 46.36 | 0.36% |
| S&P 500 | 5,892.58 | 6.03 | 0.10% |
| S&P/ASX 200 | 8,291.50 | 11.90 | 0.14% |
| SSE Composite Index | 3,388.61 | 15.34 | -0.45% |